Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anetumab ravtansine vs vinorelbine in second-line malignant pleural mesothelioma
2012-003650-88Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2015
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anetumab ravtansine in pleural mesothelioma (2 arms), sponsored by Bayer. Primary endpoint: progression-free survival. Started Oct 2015; status: completed.
02
Drugs
anetumab ravtansine
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2012-003650-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003650-88.